Last reviewed · How we verify
NCT04534673
Pegylated Interferon Lambda for Treatment of COVID-19 Infection
Phase 2 trial testing Lambda 180 mcg S.C in COVID-19 in 40 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Soroka University Medical Center |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 7 April 2020 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Lambda 180 mcg S.C — full drug profile →
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Soroka University Medical Center
Who can join
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A randomized, open-label, 2 arm, pilot trial of Lambda 180 mcg administered subcutaneously once weekly, for up to two weeks (2 injections at most), in addition to standard supportive care, compared to standard supportive care alone, in a population of COVID-19 infected patients. patients will be randomized according to 1:1 ratio to one of the 2 trial arms: Lambda 180 mcg S.C + standard care (intervention arm) or standard care only (control arm).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
PEGylated therapeutics in the clinic.
Gao Y, Joshi M, Zhao Z, Mitragotri S. · · 2024 · cited 133× · PMID 38193121 · DOI 10.1002/btm2.10600 -
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.
Ning Q, Wu D, Wang X, Xi D, et al · · 2022 · cited 64× · PMID 35197452 · DOI 10.1038/s41392-022-00907-1 -
Unbiased discovery of autoantibodies associated with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries.
Credle JJ, Gunn J, Sangkhapreecha P, Monaco DR, et al · · 2022 · cited 52× · PMID 35986181 · DOI 10.1038/s41551-022-00925-y -
The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19.
Delshad M, Tavakolinia N, Pourbagheri-Sigaroodi A, Safaroghli-Azar A, et al · · 2021 · cited 33× · PMID 33765611 · DOI 10.1016/j.intimp.2021.107586 -
Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics.
Kumar S, Çalışkan DM, Janowski J, Faist A, et al · · 2021 · cited 24× · PMID 34659259 · DOI 10.3389/fimmu.2021.752227 -
Roles of Type I and III Interferons in COVID-19.
Choi H, Shin EC. · · 2021 · cited 20× · PMID 33908208 · DOI 10.3349/ymj.2021.62.5.381 -
A translational genomics approach identifies IL10RB as the top candidate gene target for COVID-19 susceptibility.
Voloudakis G, Vicari JM, Venkatesh S, Hoffman GE, et al · · 2022 · cited 18× · PMID 36064543 · DOI 10.1038/s41525-022-00324-x -
Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2.
Garcia-Del-Barco D, Risco-Acevedo D, Berlanga-Acosta J, Martos-Benítez FD, et al · · 2021 · cited 16× · PMID 33841439 · DOI 10.3389/fimmu.2021.655528
Verify or expand the search:
- PubMed search for NCT04534673
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Soroka University Medical Center trials
Trials by the same sponsor.
- NCT06583967 — The Effect of Aerobic Exercise on an Elliptical Trainer Versus a Treadmill, in People With Multiple Sclerosis · NA · completed
- NCT05502913 — Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer · Phase 2 · recruiting
- NCT06251271 — Diagnosing Obstructive Lung Disease With Point of Care Ultrasound · completed
- NCT06221254 — A Smartphone Application for Added Psychological Wellbeing in Crohn's Disease · NA · recruiting
- NCT05230602 — Consuming of Opuntia Among Women With Fibromyalgia · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04534673 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Soroka University Medical Center
- Last refreshed: 6 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04534673.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing